Cargando…
Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma
PURPOSE: Platinum/paclitaxel-based chemotherapy is the strategy for ovarian cancer, but chemoresistance, inherent or acquired, occurs and hinders therapy. Therefore, further understanding of the mechanisms of drug resistance and adoption of novel therapeutic strategies are urgently needed. METHODS:...
Autores principales: | Gong, Ke, Dong, Yang, Wang, Liting, Duan, Yi, Yu, Jian, Sun, Ying, Bai, Min, Duan, Yourong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414939/ https://www.ncbi.nlm.nih.gov/pubmed/32801704 http://dx.doi.org/10.2147/IJN.S248667 |
Ejemplares similares
-
The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer
por: Gong, Ke, et al.
Publicado: (2021) -
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
por: O’Sullivan, Catherine, et al.
Publicado: (2016) -
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
por: Hundehege, Petra, et al.
Publicado: (2019) -
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
por: Gergely, P, et al.
Publicado: (2012) -
The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P(1)) and Hypertension (S1P(3)) in Rat
por: Fryer, Ryan M., et al.
Publicado: (2012)